Literature DB >> 25891085

Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage.

Hai-juan Sui1, Ling-ling Zhang1, Zhou Liu1, Ying Jin1.   

Abstract

AIM: The proteolytic cleavage of Tau is involved in Aβ-induced neuronal dysfunction and cell death. In this study, we investigated whether atorvastatin could prevent Tau cleavage and hence prevent Aβ1-42 oligomer (AβO)-induced neurotoxicity in cultured cortical neurons.
METHODS: Cultured rat hippocampal neurons were incubated in the presence of AβOs (1.25 μmol/L) with or without atorvastatin pretreatment. ATP content and LDH in the culture medium were measured to assess the neuronal viability. Caspase-3/7 and calpain protease activities were detected. The levels of phospho-Akt, phospho-Erk1/2, phospho-GSK3β, p35 and Tau proteins were measured using Western blotting.
RESULTS: Treatment of the neurons with AβO significantly decreased the neuronal viability, induced rapid activation of calpain and caspase-3/7 proteases, accompanied by Tau degradation and relatively stable fragments generated in the neurons. AβO also suppressed Akt and Erk1/2 kinase activity, while increased GSK3β and Cdk5 activity in the neurons. Pretreatment with atorvastatin (0.5, 1, 2.5 μmol/L) dose-dependently inhibited AβO-induced activation of calpain and caspase-3/7 proteases, and effectively diminished the generation of Tau fragments, attenuated synaptic damage and increased neuronal survival. Atorvastatin pretreatment also prevented AβO-induced decreases in Akt and Erk1/2 kinase activity and the increases in GSK3β and Cdk5 kinase activity.
CONCLUSION: Atorvastatin prevents AβO-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting calpain- and caspase-mediated Tau cleavage.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25891085      PMCID: PMC4422942          DOI: 10.1038/aps.2014.161

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  55 in total

Review 1.  The renaissance of GSK3.

Authors:  P Cohen; S Frame
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

Review 2.  Alzheimer's disease pathogenesis and therapeutic interventions.

Authors:  M S Parihar; Taruna Hemnani
Journal:  J Clin Neurosci       Date:  2004-06       Impact factor: 1.961

3.  Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease.

Authors:  G Li; E B Larson; J A Sonnen; J B Shofer; E C Petrie; A Schantz; E R Peskind; M A Raskind; J C S Breitner; T J Montine
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

4.  Reduced risk of incident AD with elective statin use in a clinical trial cohort.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Donald J Connor; Lisa M Sparks; Carolyn Liebsack
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

5.  ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures.

Authors:  Young Hae Chong; Yoo Jeong Shin; Eun Ok Lee; Rakez Kayed; Charles G Glabe; Andrea J Tenner
Journal:  J Biol Chem       Date:  2006-05-18       Impact factor: 5.157

6.  Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

Authors:  D L Sparks; D J Connor; M N Sabbagh; R B Petersen; J Lopez; P Browne
Journal:  Acta Neurol Scand Suppl       Date:  2006

7.  Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology.

Authors:  Robert A Rissman; Wayne W Poon; Mathew Blurton-Jones; Salvatore Oddo; Reidun Torp; Michael P Vitek; Frank M LaFerla; Troy T Rohn; Carl W Cotman
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease.

Authors:  Cynthia M Carlsson; Carey E Gleason; Timothy M Hess; Kimberly A Moreland; Hanna M Blazel; Rebecca L Koscik; Nathan T N Schreiber; Sterling C Johnson; Craig S Atwood; Luigi Puglielli; Bruce P Hermann; Patrick E McBride; James H Stein; Mark A Sager; Sanjay Asthana
Journal:  J Alzheimers Dis       Date:  2008-03       Impact factor: 4.472

9.  Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels.

Authors:  Eric E Abrahamson; Milos D Ikonomovic; C Edward Dixon; Steven T DeKosky
Journal:  Ann Neurol       Date:  2009-09       Impact factor: 10.422

10.  Modulation of microtubule dynamics by tau in living cells: implications for development and neurodegeneration.

Authors:  Janis M Bunker; Leslie Wilson; Mary Ann Jordan; Stuart C Feinstein
Journal:  Mol Biol Cell       Date:  2004-03-12       Impact factor: 4.138

View more
  7 in total

1.  Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.

Authors:  Zhong-Hao Zhang; Qiu-Yan Wu; Rui Zheng; Chen Chen; Yao Chen; Qiong Liu; Peter R Hoffmann; Jia-Zuan Ni; Guo-Li Song
Journal:  J Neurosci       Date:  2017-01-30       Impact factor: 6.167

2.  Atorvastatin ameliorates cognitive impairment, Aβ1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice.

Authors:  Dongsheng Zhou; Huaxia Liu; Chenli Li; Fangyan Wang; Yaosheng Shi; Lingjiang Liu; Xin Zhao; Aiming Liu; Junfang Zhang; Chuang Wang; Zhongming Chen
Journal:  Metab Brain Dis       Date:  2016-02-16       Impact factor: 3.584

3.  A new coumarin derivative, IMM-H004, attenuates okadaic acid-induced spatial memory impairment in rats.

Authors:  Xiu-yun Song; Ying-ying Wang; Shi-feng Chu; Jin-feng Hu; Peng-fei Yang; Wei Zuo; Lian-kun Song; Shuai Zhang; Nai-hong Chen
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

4.  Indirubin-3'-monoxime suppresses amyloid-beta-induced apoptosis by inhibiting tau hyperphosphorylation.

Authors:  Shu-Gang Zhang; Xiao-Shan Wang; Ying-Dong Zhang; Qing Di; Jing-Ping Shi; Min Qian; Li-Gang Xu; Xing-Jian Lin; Jie Lu
Journal:  Neural Regen Res       Date:  2016-06       Impact factor: 5.135

5.  Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies.

Authors:  Kevin C Tran; Anne Y Zeng; Tao Yang; Stephen M Massa; Frank M Longo
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.996

6.  Atorvastatin in improvement of cognitive impairments caused by amyloid β in mice: involvement of inflammatory reaction.

Authors:  Liandong Zhao; Tingting Chen; Chonghui Wang; Guoxi Li; Wenhui Zhi; Jun Yin; Qi Wan; Ling Chen
Journal:  BMC Neurol       Date:  2016-02-04       Impact factor: 2.474

7.  Intraperitoneal injection of IFN-γ restores microglial autophagy, promotes amyloid-β clearance and improves cognition in APP/PS1 mice.

Authors:  Zitian He; Yunjie Yang; Zhiwei Xing; Zejie Zuo; Rui Wang; Huaiyu Gu; Fangfang Qi; Zhibin Yao
Journal:  Cell Death Dis       Date:  2020-06-08       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.